📊 INCY Key Takeaways
Is Incyte Corp. (INCY) a Good Investment?
Incyte demonstrates exceptional fundamental strength with robust revenue growth of 21.2% YoY, industry-leading profitability metrics (29.5% operating margin, 25.0% net margin), and strong cash generation (1.4B FCF). The company maintains excellent financial health with a 3.32x current ratio and substantial cash reserves of 3.1B, providing strategic flexibility despite elevated long-term debt.
Incyte shows strong operating fundamentals with 21.2% revenue growth, a 29.5% operating margin, and robust free cash flow generation, indicating that growth is translating into real profitability and cash. Liquidity is also strong, with over $3.1B in cash and current and quick ratios above 3x. The main constraint on conviction is that parts of the leverage data appear internally inconsistent, and net income was flat despite strong top-line growth.
Why Buy Incyte Corp. Stock? INCY Key Strengths
- Strong topline growth of 21.2% YoY with revenue reaching 5.1B
- Exceptional profitability with 29.5% operating margin and 25.0% net margin
- Robust cash generation with 1.4B operating cash flow and 26.5% FCF margin
- Excellent returns on capital with 24.9% ROE and 18.5% ROA
- Strong liquidity position with 3.32x current ratio and 3.1B cash reserves
- Significant insider activity with 19 Form 4 filings in last 90 days indicating confidence
- Strong revenue growth combined with high operating and net margins supports high-quality earnings
- Free cash flow of $1.36B and a 26.5% FCF margin indicate excellent cash conversion
- Large cash balance and strong liquidity ratios provide balance sheet flexibility
INCY Stock Risks: Incyte Corp. Investment Risks
- Elevated leverage with 3.70x debt-to-equity ratio and 19.1B long-term debt relative to 7.0B total assets
- High debt burden requires sustained profitability and cash flow to service obligations
- Research and development-heavy sector (SIC 8731) carries inherent execution and clinical development risks
- Net income essentially flat YoY (+0.0%) despite revenue growth, suggesting potential margin pressure or one-time items
- Reported long-term debt exceeds total liabilities, suggesting a possible data-quality issue that clouds leverage assessment
- Net income was flat year over year despite double-digit revenue growth, which may indicate rising costs or non-operating offsets
- Gross profit and gross margin are unavailable, limiting visibility into core margin durability
Key Metrics to Watch
- Revenue growth trajectory and pipeline advancement for maintaining 20%+ growth
- Operating margin sustainability and ability to expand given flat net income
- Debt repayment progress and debt-to-equity ratio improvement below 3.0x
- Free cash flow consistency and capital allocation decisions
- R&D spending efficiency and clinical trial success rates
- Sustained net income and free cash flow growth relative to revenue growth
- Clarification of debt, total liabilities, and overall leverage from future SEC filings
Incyte Corp. (INCY) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 26.5% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 3.32x current ratio provides a solid financial cushion.
INCY Profit Margin, ROE & Profitability Analysis
INCY vs Healthcare Sector: How Incyte Corp. Compares
How Incyte Corp. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Incyte Corp. Stock Overvalued? INCY Valuation Analysis 2026
Based on fundamental analysis, Incyte Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Incyte Corp. Balance Sheet: INCY Debt, Cash & Liquidity
INCY Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Incyte Corp.'s revenue has grown significantly by 72% over the 5-year period, indicating strong business expansion. The most recent EPS of $2.65 reflects profitable operations.
INCY Revenue Growth, EPS Growth & YoY Performance
INCY Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.1B | $106.5M | $0.54 |
| Q2 2025 | $1.0B | $158.2M | $-1.24 |
| Q1 2025 | $880.9M | $158.2M | $0.75 |
| Q3 2024 | $919.0M | $21.7M | $0.54 |
| Q2 2024 | $954.6M | $21.7M | $0.90 |
| Q1 2024 | $808.7M | $21.7M | $0.10 |
| Q3 2023 | $823.3M | $21.7M | $0.50 |
| Q2 2023 | $911.4M | $21.7M | $0.72 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Incyte Corp. Dividends, Buybacks & Capital Allocation
INCY SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Incyte Corp. (CIK: 0000879169)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INCY
What is the AI rating for INCY?
Incyte Corp. (INCY) has a Combined AI Rating of BUY from Claude (STRONG BUY) and ChatGPT (BUY) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are INCY's key strengths?
Claude: Strong topline growth of 21.2% YoY with revenue reaching 5.1B. Exceptional profitability with 29.5% operating margin and 25.0% net margin. ChatGPT: Strong revenue growth combined with high operating and net margins supports high-quality earnings. Free cash flow of $1.36B and a 26.5% FCF margin indicate excellent cash conversion.
What are the risks of investing in INCY?
Claude: Elevated leverage with 3.70x debt-to-equity ratio and 19.1B long-term debt relative to 7.0B total assets. High debt burden requires sustained profitability and cash flow to service obligations. ChatGPT: Reported long-term debt exceeds total liabilities, suggesting a possible data-quality issue that clouds leverage assessment. Net income was flat year over year despite double-digit revenue growth, which may indicate rising costs or non-operating offsets.
What is INCY's revenue and growth?
Incyte Corp. reported revenue of $5.1B.
Does INCY pay dividends?
Incyte Corp. does not currently pay dividends.
Where can I find INCY SEC filings?
Official SEC filings for Incyte Corp. (CIK: 0000879169) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INCY's EPS?
Incyte Corp. has a diluted EPS of $6.41.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INCY a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Incyte Corp. has a BUY rating with 82% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is INCY stock overvalued or undervalued?
Valuation metrics for INCY: ROE of 24.9% (sector avg: 15%), net margin of 25.0% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy INCY stock in 2026?
Our dual AI analysis gives Incyte Corp. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is INCY's free cash flow?
Incyte Corp.'s operating cash flow is $1.4B, with capital expenditures of $48.7M. FCF margin is 26.5%.
How does INCY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 25.0% (avg: 12%), ROE 24.9% (avg: 15%), current ratio 3.32 (avg: 2).
Is Incyte Corp. carrying too much debt?
INCY has a debt-to-equity ratio of 3.70x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 3.32 suggests adequate short-term liquidity.